ER/PR | Search

Trials

74 participants · First posted Jan 6, 2021

Completed

NCT02654431

Identification and Semi -Quantification of ER/PR Proteins Expression

350 participants · First posted Jan 13, 2016

Completed

NCT00580333

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

51 participants · First posted Dec 24, 2007

Drugs

View all 277 →

aprepitant;pramipexole ER

Small Molecule

Approved

Tapentadol(Nucynta)

Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Severe Acute Pain +1 more

C₁₄H₂₃NO · Rx

PR-00012

Organizations

View all 8 →

JOLLC Gurabo, PR

United States

NOVIS PR LLC

United States

Trenders

News

View all 520 →

last year

NPPA Committee Identifies Patent Discrepancies in Intas' Clozapine ER Pricing Application

last year

Elacestrant Plus Abemaciclib Shows Promise in Pretreated ER+/HER2- Metastatic Breast Cancer

last year

Trials

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Identification and Semi -Quantification of ER/PR Proteins Expression

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Drugs

aprepitant;pramipexole ER

Tapentadol(Nucynta)

PR-00012

Organizations

JOLLC Gurabo, PR

NOVIS PR LLC

Trenders

News

NPPA Committee Identifies Patent Discrepancies in Intas' Clozapine ER Pricing Application

Elacestrant Plus Abemaciclib Shows Promise in Pretreated ER+/HER2- Metastatic Breast Cancer

Trevi Therapeutics Presents Nalbuphine ER Data at Major Respiratory Conferences Following Positive Phase 2 Trials